When researchers gathered every antidepressant trial drug companies had filed with the Food and Drug Administration, the published and the buried alike, they found something that should change how we think about getting better: most of the improvement people felt on the medication was matched, point for point, by people taking a sugar pill.
The analysis came from Irving Kirsch and colleagues, published in 2008, pooling thirty-five trials of four widely used antidepressants. By their accounting, more than eighty percent of the drug's effect also appeared in the placebo group. The average gap between drug and dummy pill came to fewer than two points on the standard depression scale, a difference smaller than the threshold British guidelines use to call a change clinically meaningful. The medication worked. The striking part was how much of that work the body and mind were already doing on their own, prompted by little more than the act of being treated.
What the gap actually means
A finding this provocative needs its counterweight, and it has a strong one. In 2018 Andrea Cipriani led the largest comparison ever assembled, five hundred and twenty-two trials and more than a hundred and sixteen thousand people, and every one of the twenty-one antidepressants studied outperformed placebo. So the drugs are real. What both findings share is the size of the placebo's contribution. Expectation, the ritual of care, the weekly visit, the belief that relief is coming, these are not noise in the experiment. They are part of the medicine.
The pill carries a chemical and a promise, and the body answers both.
Using the part you control
This is where the science becomes practical and even hopeful. If expectation contributes that much, then the way a person enters their own treatment matters to the result. Showing up with the belief that change is possible, keeping the appointments, building the supportive routine around the prescription, leaning on the people who check in, all of this is the active ingredient that the trials kept measuring in the placebo arm. It is the share of recovery that belongs to the patient and the people around them.
One caution belongs here in plain words. None of this is a reason to stop a medication, and the drug-placebo gap widens in the most severe depression, where the prescription matters most plainly. The lesson is not to abandon treatment but to bring the whole self to it. Kirsch worked from data the drug makers themselves submitted, which gives the number its weight, and depression is unusually responsive to hope, which is part of why the effect runs so large. What stands is quietly empowering: a real part of feeling better starts with the expectation that you will.